Inhibiting MAGL (which breaks down the endocannabinoid 2-AG) produced a discriminative stimulus in mice that felt like cannabis to them, suggesting MAGL normally prevents 2-AG from reaching psychoactive levels.
Read this if you are interested in how the brain naturally controls its own cannabis-like chemicals and what happens when that control is disrupted.
MAGL normally prevents 2-AG from reaching levels that produce cannabis-like intoxication
What the researchers found
This study demonstrated that blocking MAGL, the enzyme that breaks down the endocannabinoid 2-AG, produces subjective effects in mice that are indistinguishable from those produced by THC-like drugs.
12 of 13 mice successfully learned to discriminate the MAGL inhibitor MJN110 from vehicle, and the CB1 receptor antagonist rimonabant blocked this discriminative stimulus, confirming it works through CB1 receptors.
The synthetic cannabinoid CP55,940, another MAGL inhibitor (JZL184), and the dual FAAH/MAGL inhibitor SA-57 all fully substituted for MJN110, meaning they felt the same to the mice. However, the FAAH inhibitor PF-3845 (which boosts anandamide instead of 2-AG) did not substitute, showing that enhancing anandamide alone does not produce cannabis-like subjective effects.
Combining FAAH inhibition with MAGL inhibition made the MAGL effect stronger (1.6x leftward shift), suggesting anandamide and 2-AG interact.
The findings suggest MAGL normally acts as a "brake" on 2-AG, keeping it below levels that would produce cannabis-like intoxication.
Why it matters
This study reveals that the brain's own endocannabinoid system is capable of producing cannabis-like intoxication if 2-AG accumulates beyond normal levels. Understanding this has implications for MAGL inhibitor drug development, which must consider abuse potential.
The numbers in context
12 of 13 mice learned the discrimination. FAAH inhibitor caused 1.6x (95% CI 1.1-2.2) leftward shift of MAGL inhibitor dose-response. Rimonabant dose-dependently blocked the discriminative stimulus.
How the study worked
Drug discrimination paradigm in C57BL/6J mice trained to distinguish MAGL inhibitor MJN110 from vehicle. Substitution tests with multiple compounds (CP55,940, SA-57, JZL184, PF-3845, ABHD6 inhibitor, COX-2 inhibitor, nicotine, diazepam). Rimonabant used to confirm CB1 mediation.
What this study cannot tell us
Mouse drug discrimination may not perfectly predict human subjective experiences. The study used a single MAGL inhibitor for training. The ecological relevance of pharmacologically elevated 2-AG levels to natural endocannabinoid function is uncertain.
How to read the evidence
Well-controlled drug discrimination study with comprehensive substitution testing. Preliminary because the subjective experience parallel between mice and humans is inferred.
When this study was published
Published in 2017.
The bigger picture
The distinction between MAGL and FAAH inhibition is clinically relevant. FAAH inhibitors (boosting anandamide) do not produce cannabis-like subjective effects, making them potentially safer therapeutic agents. MAGL inhibitors (boosting 2-AG) do produce such effects, suggesting they carry abuse potential similar to cannabis.
Questions still open
- Do MAGL inhibitors have abuse potential in humans similar to cannabis? Could partial MAGL inhibitors provide therapeutic benefit without producing intoxicating levels of 2-AG? Why does anandamide enhancement not produce cannabis-like subjective effects while 2-AG enhancement does?
Common questions
Can the brain produce its own cannabis-like high?
What is the difference between anandamide and 2-AG?
Read the original research
Inhibition of the endocannabinoid-regulating enzyme monoacylglycerol lipase elicits a CB1 receptor-mediated discriminative stimulus in mice.
Neuropharmacology, 125, 80-86
Citation
Owens, Robert A; Mustafa, Mohammed A; Ignatowska-Jankowska, Bogna M; Damaj, M Imad; Beardsley, Patrick M; Wiley, Jenny L; Niphakis, Micah J; Cravatt, Benjamin F; Lichtman, Aron H. (2017). Inhibition of the endocannabinoid-regulating enzyme monoacylglycerol lipase elicits a CB1 receptor-mediated discriminative stimulus in mice.. Neuropharmacology, 125, 80-86. https://doi.org/10.1016/j.neuropharm.2017.06.032
Explore the wider topic
- How THC Affects Your Amygdala: The Brain's Threat Detector and Cannabis
- The Anandamide Connection: Your Body's Natural Bliss Molecule
- How Long for Cannabinoid Receptors to Return to Normal
- Cannabis and the Developing Brain: What Every Teenager (and Parent) Should Know
- Why Can't I Enjoy Anything Without Weed? The Science Behind It
- Dopamine Recovery After Quitting Weed: What the Science Says
- The Endocannabinoid System Explained Simply: What It Does and Why It Matters
- Your Endocannabinoid System Explained: Why Withdrawal Happens
- Your Nervous System After Quitting Weed: Fight or Flight
- Using Weed Under 18: What It Does to Your Developing Brain
- What THC Does to Your Brain: Why Withdrawal Happens
- THC and Your Prefrontal Cortex: What Cannabis Does to Your Decision-Making Brain
- Weed, Cortisol, and Stress: What Cannabis Does to Your Stress Hormones
- Weed and Memory: What the Science Says About THC and Your Hippocampus
- Weed and Motivation: Is Amotivational Syndrome Real?
- Weed and Your Nervous System: What THC Actually Does to Your Brain and Body
- How Weed Rewires Your Reward System (And How to Reset It)